United States · FDA National Drug Code directory

MiraLAX

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
11523-4357_51040c1b-71bf-bb83-e063-6294a90aca4e
Product NDC
11523-4357
Form
POWDER, FOR SOLUTION
Composition / generic term
Polyethylene Glycol 3350
Labeler
Bayer HealthCare LLC.
Marketing category
NDA
Marketing start / end (source format)
20070201
Source listing expiry
20271231

Source-listed ingredients

  • POLYETHYLENE GLYCOL 3350 — 17 g/17g

These values do not establish equivalence or a dose recommendation.

Packages

  • 2 CARTON in 1 CARTON (11523-4357-2) / 20 PACKET in 1 CARTON / 17 g in 1 PACKET · 11523-4357-2
  • 2 BOTTLE, PLASTIC in 1 PACKAGE, COMBINATION (11523-4357-3) / 578 g in 1 BOTTLE, PLASTIC · 11523-4357-3
  • 24 PACKET in 1 CARTON (11523-4357-5) / 17 g in 1 PACKET · 11523-4357-5

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →